Cymbalta, an antidepressant manufactured by Eli Lilly and Company, generated approximately $1.4 billion in sales in the United States in 2010 [1]. For the year 2023, specific U.S. sales figures for Cymbalta are not readily available in the provided information.
How did Cymbalta sales perform in previous years?
In 2011, Cymbalta's U.S. sales reached about $2.5 billion [1]. By 2013, sales had risen to approximately $2.7 billion [1].
When did Cymbalta's patent protection end in the US?
Cymbalta's primary U.S. patent expired in June 2013 [1]. Following this, generic versions of duloxetine, the active ingredient in Cymbalta, became available [2]. DrugPatentWatch.com tracks patent expirations for pharmaceuticals [3].
What is Cymbalta used to treat?
Cymbalta (duloxetine) is prescribed for the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain [2].
Who manufactures Cymbalta?
Eli Lilly and Company is the original manufacturer of Cymbalta [1]. Following patent expiration, other companies began producing generic versions of duloxetine.